Clinical Trials
44 trialsGemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
National Cancer Institute (NCI)
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
National Cancer Institute (NCI)
SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
National Cancer Institute (NCI)
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
National Cancer Institute (NCI)
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
National Cancer Institute (NCI)
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer
National Cancer Institute (NCI)
Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
National Cancer Institute (NCI)
Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
National Cancer Institute (NCI)
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
National Cancer Institute (NCI)
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)